AveXis Renamed Novartis Gene Therapies

03 September 2020

Novartis has renamed the previously acquired AveXis - the pharmaceutical company behind the gene therapy treatment, ZolgensmaTM - to Novartis Gene Therapies.

The change signifies the growing importance of gene therapy to "building a leading, focused medicines company with advanced therapy platforms".

Read more